Triapine(Triapine) - 药物靶点：RNR_在研适应症：腺鳞癌，宫颈鳞状细胞癌，鳞状细胞癌_专利_临床

概要

基本信息

药物类型

小分子化药

别名

Triapine、3-AP、NSC#663249

+ [5]

靶点

RNR

作用机制

RNR抑制剂(核糖核苷酸还原酶复合体抑制剂)

治疗领域

肿瘤泌尿生殖系统疾病其他疾病+ [2]

在研适应症

腺鳞癌宫颈鳞状细胞癌鳞状细胞癌+ [10]

非在研适应症

腺泡细胞癌急性早幼粒细胞白血病食管腺癌+ [58]

原研机构

Nanotherapeutics, Inc.

在研机构

National Cancer Institute

Nanopharmaceutics, Inc.初创企业

Nanotherapeutics, Inc.

非在研机构

Vion Pharmaceuticals, Inc.

最高研发阶段临床3期

首次获批日期-

最高研发阶段(中国)-

特殊审评-

登录后查看时间轴

结构

分子式C7H9N5S

InChIKeyXMYKNCNAZKMVQN-UHFFFAOYSA-N

CAS号143621-35-6

关联

33

项与 Triapine 相关的临床试验

NCT06410248 / Active, not recruiting临床1期IIT

A Phase 1 Adaptive Dose Escalation With Dose Expansion Study of Triapine in Combination With Temozolomide (TMZ) for Patients With Recurrent Glioblastoma

This phase I trial tests the safety, side effects, and best dose of triapine in combination with temozolomide in treating patients with glioblastoma that has come back after a period of improvement (recurrent). Triapine inhibits an enzyme responsible for producing molecules required for the production of deoxyribonucleic acid (DNA), which may inhibit tumor cell growth. Temozolomide is in a class of medications called alkylating agents. It works by damaging the cell's DNA and may kill tumor cells and slow down or stop tumor growth. Giving triapine in combination with temozolomide may be safe, tolerable, and/or effective in treating patients with recurrent glioblastoma.

开始日期2024-07-23

申办/合作机构

Northwestern University

[+2]

NCT05724108 / Recruiting临床2期IIT

A Phase II Randomized Control Trial of Triapine Plus Lutetium Lu 177 Dotatate Versus Lutetium Lu 177 Dotatate Alone for Well-Differentiated Somatostatin Receptor-Positive Neuroendocrine Tumors

This phase II trial compares the effect of adding triapine to lutetium Lu 177 dotatate versus lutetium Lu 177 dotatate alone (standard therapy) in shrinking tumors or slowing tumor growth in patients with neuroendocrine tumors that have spread from where they first started (primary site) to other places in the body (metastatic). Triapine may stop the growth of tumor cells by blocking some of the enzymes needed for deoxyribonucleic acid synthesis and cell growth. Lutetium Lu 177 dotatate is a radioactive drug. It binds to a protein called somatostatin receptor, which is found on some neuroendocrine tumor cells. Lutetium Lu 177 dotatate builds up in these cells and gives off radiation that may kill them. It is a type of radioconjugate and a type of somatostatin analog. Giving triapine in combination with lutetium Lu 177 dotatate may be more effective at shrinking tumors or slowing tumor growth in patients with metastatic neuroendocrine tumors than the standard therapy of lutetium Lu 177 dotatate alone.

开始日期2023-08-30

申办/合作机构

National Cancer Institute

NCT04494113 / Recruiting早期临床1期IIT

A Phase 0 Window-of-Opportunity Pharmacodynamic Trial of Triapine (NSC# 663249) in Uterine Corpus Serous Adenocarcinoma

This early phase I trial investigates the response to the anti-cancer drug, triapine, in uterine cancers by using markers from tissue samples at the time of removal of the uterus, ovaries, and fallopian tubes (hysterectomy and bilateral salpingo-oophorectomy). Triapine may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Adding triapine to the usual approach of surgery followed by chemotherapy alone or in combination with radiation therapy may help to slow the growth of uterine cancer.

开始日期2022-02-08

申办/合作机构

National Cancer Institute

100 项与 Triapine 相关的临床结果

登录后查看更多信息

100 项与 Triapine 相关的转化医学

登录后查看更多信息

100 项与 Triapine 相关的专利（医药）

登录后查看更多信息

310

项与 Triapine 相关的文献（医药）

2024-12-01·BIOORGANIC CHEMISTRY

Synthesis of 5-hydroxyisatin thiosemicarbazones, spectroscopic investigation, protein-ligand docking, and in vitro anticancer activity

Article

作者: Nath Yadav, Paras ; Sharma, Pratibha ; Chikara, Anshul ; Kumar, Piyush ; Barua, Ayanti ; Adhikari Subin, Jhashanath ; Raj Pokharel, Yuba ; Chaudhary, Upendra ; Mahiya, Kuldeep

A series of novel modifications were performed at the N(4) position of 5-hydroxyisatin thiosemicarbazone (TSC). The structure-activity approach is applied to design and synthesize derivatives by condensing thiosemicarbazides with 5-hydroxy isatin. The TSCs were characterized by various spectroscopic techniques viz. FTIR, ¹H NMR, ¹³C NMR, UV-Vis, HRMS data, CHN elemental analysis, and single crystal X-ray diffraction. Biological evaluation of the synthesized compounds revealed the anticancer potency of the TSC analogues against breast cancer (MD-AMD-231, MCF-7), lung cancer (A549, NCI-H460), prostate cancer (PC3), and skin cancer (A431). The molecules, L2, L3, and L6 showed activity in the micromolar range (IC₅₀; 0.19-2.19 μM). L6 exhibited the highest potency against skin cancer A431 cell line, with an IC₅₀ of 0.19 μM compared to 1.8 μM with triapine and showed low toxicity against PNT-2 cells with an SI index of >100 μM. The mechanistic study revealed that L6 inhibited cancer cell proliferation, colony formation, and 3-dimensional spheroid formation by targeting the Ras/MAPK axis. It induced DNA damage and impaired DNA damage repair machinery, which led to the accumulation of DSB. Also, it lowered the ERK1/2 expression, which affected the caspase 3 activity and showed higher binding affinity compared to the FDA-approved drug Lenalidomide in molecular docking studies. Our findings demonstrated the possible future anticancer drug potency of L6 in the skin cancer A431 cells.

2024-12-01·GLIA

Identification of astrocyte‐like cells in an adult ascidian during regeneration of the central nervous system

Article

作者: Monteiro‐de‐Barros, Cintia ; de Andrade Gomes, Carlos Augusto Borges ; Portal, Taynan Motta ; Nunes‐da‐Fonseca, Rodrigo ; Allodi, Silvana ; Medina, Bianca Nicole Santos Paes

Abstract:

The mechanisms underlying regeneration of the central nervous system (CNS) following lesions have been studied extensively in both vertebrate and invertebrate models. To shed light on regeneration, ascidians, a sister group of vertebrates and with remarkable ability to regenerate their brains, constitute an appropriate model system. Glial cells have been implicated in regeneration in vertebrates; however, their role in the adult ascidian CNS regeneration is unknown. A model of degeneration and regeneration using the neurotoxin 3‐acetylpyridine (3AP) in the brain of the ascidian Styela plicata was used to identify astrocyte‐like cells and investigate their role. We studied the CNS of control ascidians (injected with artificial sea water) and of ascidians whose CNS was regenerating (1 and 10 days after the injection with 3AP). Our results show that the mRNA of the ortholog of glutamine synthetase (GS), a glial‐cell marker in vertebrates, is increased during the early stages of regeneration. Confirming the identity of GS, the protein was identified via immunostaining in a cell population during the same regeneration stage. Last, a single ortholog of GS (GSII) is present in ascidian and amphioxus genomes, while two types exist in fungi, some invertebrates, and vertebrates, suggesting that ascidians have lost the GSI type. Taken together, our findings revealed that a cell population expressing glial‐cell markers may play a role in regeneration in adult ascidians. This is the first report of astrocyte‐like cells in the adult ascidian CNS, and contributes to understanding of the evolution of glial cells among metazoans.

2024-10-01·NEUROPEPTIDES

Bromelain decreases oxidative stress and Neuroinflammation and improves motor function in adult male rats with cerebellar Ataxia induced by 3-acetylpyridine

Article

作者: Sani, Mojtaba ; Babaei, Mohammad Reza ; Nourirad, Seyedeh Naghmeh ; Chegeni, Maryam Jahani ; Tahvildari, Azin ; Bayat, Amir-Hossein ; Lahiji, Hormoz ; Khakpour, Yaser ; Eskandari, Neda ; Roustaee, Susan ; Balaghirad, Nika ; Hashemabady, Maryam ; Aliaghaei, Abbas ; Sagharichi, Mastooreh ; Bahar, Reza ; Mehranpour, Maryam ; Fathi, Mobina ; Vakili, Kimia ; Taghizadeh, Mohammad

Bromelain is a plant-based molecule with antioxidant, antithrombotic, anticancer, and anti-inflammatory properties. Bromelain has been shown to reduce the release of inflammatory cytokines. This study aimed to determine whether bromelain can prevent ataxia in rats caused by 3-acetylpyridine (3-AP). Thirty-six albino rats were divided into the control, 3-AP, and 3-AP + Brom groups. In the 3-AP + Brom group, bromelain was injected intraperitoneally at 40 mg/kg daily for 30 days. Various techniques such as rotarod, electromyography (EMG), elevated plus maze, IHC, and Sholl analysis were used to evaluate the possible effects of bromelain on cerebellar neurons and glial cells. The results demonstrated significant improvements in most of the 3-AP + Brom, including motor coordination, neuromuscular response, anxiety, oxidative capacity, microgliosis, astrogliosis, cell death, and morphological variables compared to the 3-AP group. The mechanism of action of bromelain in restoring cerebellar ataxia needs further investigation, but it may be a candidate to help restore degeneration in animals with ataxia.

4

项与 Triapine 相关的新闻（医药）

2024-05-14

·PRNewswire

Nanopharmaceutics and Northwestern University Announce Initiation of Phase I Adaptive Dose Escalation Clinical Study with Dose Expansion of Oral Triapine® in Combination with Temozolomide (TMZ) for Patients with Recurrent Glioblastoma

ALACHUA, Fla. and CHICAGO, May 14, 2024 /PRNewswire/ -- Nanopharmaceutics, Inc. (OTC:TGRP), a clinical-stage pharmaceutical development company, announced the initiation of a Phase I clinical study with the Robert H. Lurie Comprehensive Cancer Center of Northwestern University "A Phase 1 Adaptive Dose Escalation With Dose Expansion Study of Triapine in Combination With Temozolomide (TMZ) for Patients With Recurrent Glioblastoma" (ClinicalTrials.gov Identifier: NCT06410248). The primary objective of this phase 1 study will be to determine the recommended phase 2 dose (RP2D) for Triapine® in combination with temozolomide (TMZ). Secondary objectives include evaluation of the safety profile of Triapine® in combination with temozolomide (TMZ), progression-free survival (PFS), overall survival (OS), overall response rate (ORR) per RANO criteria, and quality of life per FACT-Br. The study will recruit 40-45 patients with an established diagnosis of recurrent glioblastoma, and there will be an exploratory arm to investigate drug delivery into brain tumor tissue and target engagement in a cohort who are surgical candidates for re-resection of recurrent glioblastoma. Funding for the study is provided by BrainUp. Oral Triapine® has been shown to be safe, tolerable, and convenient in multiple clinical studies. Ribonucleotide Reductase (RNR) Regulatory Subunit 2 (RRM2) targeting with Triapine® may overcome chemoresistance and improve the clinical efficacy of TMZ therapy. Preliminary research from Dr. Atique Ahmed's lab at Northwestern University has uncovered a critical factor that helps glioblastoma, an aggressive brain cancer, resist chemotherapy treatment. About the Robert H. Lurie Comprehensive Cancer Center of Northwestern University The Robert H. Lurie Comprehensive Cancer Center of Northwestern University is a National Cancer Institute-designated Comprehensive Cancer Center located on Northwestern Memorial Hospital's downtown medical campus in the Streeterville neighborhood of Chicago, Illinois, United States. About BrainUp BrainUp is a nonprofit founded by Dan & Meg Kresach of Frankfort, Illinois. They founded BrainUp after their only child Olivia, was diagnosed 10 years ago with a Glioblastoma at the age of 22 years old. She died on April 19, 2014. The Kresachs formed BrainUp to fund brain cancer research. They have an annual run/walk to raise money for brain cancer research. They have funded over 1.2 million dollars supporting brain cancer research and trials at Chicago healthcare institutions. BrainUp is the financial supporter of Karan Dixit, M.D. (PI) and Atique Ahmed, Ph.D of Northwestern University Chicago, Illinois. To learn more about BrainUp, visit brainup.ngo About Nanopharmaceutics, Inc. Nanopharmaceutics, Inc. is a clinical-stage specialty pharmaceutical company developing oral, topical, and injectable products for cancer, central nervous system (CNS) disorders, and infectious diseases. Leveraging its expertise in nanoparticle and fine-particle formulations, which can specifically be used to improve hard-to-deliver BCS category II and IV drugs, Nanopharmaceutics is focused on formulation development aimed at improving drug absorption and stability. Contact: Nanopharmaceutics, Inc. (OTC: TGRP) James D. Talton, Ph.D. President and Chief Executive Officer 386-401-6304 SOURCE Nanopharmaceutics, Inc.

临床1期寡核苷酸

2022-11-02

·PRNewswire

Nanopharmaceutics, Inc. Announces the End of Patient Recruitment for the National Cancer Institute (NCI) Sponsored Phase 3 Clinical Study in Advanced-Stage Cervical and Vaginal Cancers with Cisplatin During Radiation Therapy with and without Triapine®

ALACHUA, Fla., Nov. 2, 2022 /PRNewswire/ -- Nanopharmaceutics, Inc., a clinical-stage pharmaceutical development company, today announced completion of patient enrollment in the 450 patient Phase 3 clinical study sponsored by the NCI, part of the National Institutes of Health, and led by NCI funded network group, NRG Oncology, with participation of the NCI National Clinical Trials Network (NCTN), "A Randomized Phase III Trial of Radiation Therapy and Cisplatin Alone or in Combination with Intravenous Triapine in Women with Newly Diagnosed Bulky Stage IB2, Stage II, IIIB, or IVA Cancer of the Uterine Cervix or Stage II-IVA Vaginal," (NRG-GY006, ClinicalTrials.gov Identifier: NCT02466971). The randomized phase 3 trial is evaluating radiation therapy and cisplatin with Nanopharmaceutics' proprietary formulation of Triapine® compared to the standard radiation therapy and cisplatin, alone, in treating patients with newly diagnosed stage IB2, II, or IIIB-IVA cervical cancer or stage II-IVA vaginal cancer. Radiation therapy uses high energy protons to kill tumor cells and shrink tumors. Drugs used in chemotherapy, such as cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, stopping them from dividing, or by stopping them from spreading. Triapine® may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. It is not yet known whether radiation therapy and cisplatin are more effective with Triapine® Injection in treating cervical or vaginal cancer. 450 patients were enrolled in the study, which was performed under a Cooperative Research and Development Agreement (CRADA) between NCI and Nanopharmaceutics. About Triapine® Triapine® is a synthetic heterocyclic carboxaldehyde thiosemicarbazone with potential antineoplastic activity being studied in the treatment of cancer. It is a type of ribonucleotide reductase inhibitor. Also called 3-aminopyridine-2-carboxaldehyde thiosemicarbazone and 3-AP, Triapine® inhibits the enzyme ribonucleotide reductase, resulting in the inhibition of the conversion of ribonucleoside diphosphates to deoxyribonucleotides necessary for DNA synthesis. About Nanopharmaceutics, Inc. Nanopharmaceutics, Inc. is a clinical-stage specialty pharmaceutical company developing oral, topical, and injectable products for cancer, central nervous system (CNS) disorders, and infectious diseases. Leveraging its expertise in nanoparticle and fine-particle formulations, which can specifically be used to improve hard-to-deliver Biopharmaceutics Classification System (BCS) category II and IV drugs, Nanopharmaceutics is focused on formulation development aimed at improving drug absorption and stability. Contact: Nanopharmaceutics, Inc. James D. Talton, Ph.D. President and Chief Executive Officer 352-401-6304 [email protected] SOURCE Nanopharmaceutics, Inc.

放射疗法

2022-11-02

·BioSpace

Nanopharmaceutics, Inc. Announces the End of Patient Recruitment for the NCI Sponsored Phase 3 Clinical Study in Advanced-Stage Cervical and Vaginal Cancers with Cisplatin During Radiation Therapy with and without Triapine®

ALACHUA, Fla., Nov. 2, 2022 /PRNewswire/ -- Nanopharmaceutics, Inc., a clinical-stage pharmaceutical development company, today announced completion of patient enrollment in the 450 patient Phase 3 clinical study sponsored by the NCI, part of the National Institutes of Health, and led by NCI funded network group, NRG Oncology, with participation of the NCI National Clinical Trials Network (NCTN), "A Randomized Phase III Trial of Radiation Therapy and Cisplatin Alone or in Combination with Intravenous Triapine in Women with Newly Diagnosed Bulky Stage IB2, Stage II, IIIB, or IVA Cancer of the Uterine Cervix or Stage II-IVA Vaginal," (NRG-GY006, ClinicalTrials.gov Identifier: NCT02466971). The randomized phase 3 trial is evaluating radiation therapy and cisplatin with Nanopharmaceutics' proprietary formulation of Triapine® compared to the standard radiation therapy and cisplatin, alone, in treating patients with newly diagnosed stage IB2, II, or IIIB-IVA cervical cancer or stage II-IVA vaginal cancer. Radiation therapy uses high energy protons to kill tumor cells and shrink tumors. Drugs used in chemotherapy, such as cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, stopping them from dividing, or by stopping them from spreading. Triapine® may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. It is not yet known whether radiation therapy and cisplatin are more effective with Triapine® Injection in treating cervical or vaginal cancer. 450 patients were enrolled in the study, which was performed under a Cooperative Research and Development Agreement (CRADA) between NCI and Nanopharmaceutics. About Triapine® Triapine® is a synthetic heterocyclic carboxaldehyde thiosemicarbazone with potential antineoplastic activity being studied in the treatment of cancer. It is a type of ribonucleotide reductase inhibitor. Also called 3-aminopyridine-2-carboxaldehyde thiosemicarbazone and 3-AP, Triapine® inhibits the enzyme ribonucleotide reductase, resulting in the inhibition of the conversion of ribonucleoside diphosphates to deoxyribonucleotides necessary for DNA synthesis. About Nanopharmaceutics, Inc. Nanopharmaceutics, Inc. is a clinical-stage specialty pharmaceutical company developing oral, topical, and injectable products for cancer, central nervous system (CNS) disorders, and infectious diseases. Leveraging its expertise in nanoparticle and fine-particle formulations, which can specifically be used to improve hard-to-deliver Biopharmaceutics Classification System (BCS) category II and IV drugs, Nanopharmaceutics is focused on formulation development aimed at improving drug absorption and stability. Contact: Nanopharmaceutics, Inc. James D. Talton, Ph.D. President and Chief Executive Officer 352-401-6304 jtalton@nanopharmaceutics.com View original content: SOURCE Nanopharmaceutics, Inc.

放射疗法

100 项与 Triapine 相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
-	-	-	DB11940

研发状态

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
腺鳞癌	临床3期	美国	National Cancer Institute	2016-05-10
腺鳞癌	临床3期	加拿大	National Cancer Institute	2016-05-10
腺鳞癌	临床3期	波多黎各	National Cancer Institute	2016-05-10
宫颈鳞状细胞癌	临床3期	美国	National Cancer Institute	2016-05-10
宫颈鳞状细胞癌	临床3期	加拿大	National Cancer Institute	2016-05-10
宫颈鳞状细胞癌	临床3期	波多黎各	National Cancer Institute	2016-05-10
鳞状细胞癌	临床3期	美国	National Cancer Institute	2016-05-10
鳞状细胞癌	临床3期	加拿大	National Cancer Institute	2016-05-10
鳞状细胞癌	临床3期	波多黎各	National Cancer Institute	2016-05-10
子宫颈腺癌	临床3期	美国	National Cancer Institute	2016-05-10

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT02595879 (CTgov)	临床1期	腺鳞癌 \| 阴道腺癌 \| 局部晚期宫颈癌 ... 更多	21	triapine (All Participants)	構顧襯膚艱夢窪鹹積鹽(憲觸糧廠鹹觸餘觸觸蓋) = 廠顧夢鏇膚願遞壓艱鑰蓋鹽膚積壓網製選餘衊 (醖遞艱膚鬱獵窪構構蓋, 範襯遞遞淵簾願衊壓膚 ~ 醖窪淵鹹獵繭製鹹構膚)	-	2024-10-16
				Triapine (Triapine (100mg) + Chemoradiation))	鑰襯獵選積淵鬱糧糧廠(鑰鑰簾膚範積願範鑰遞) = 鹽遞鏇鹹襯醖糧顧願夢願製獵鑰夢鏇蓋艱築鬱 (窪淵夢網襯蓋構淵遞鏇, 鬱膚糧網構網淵範鏇鹹 ~ 窪鬱選淵簾壓淵觸艱積) 更多
NCT02466971 (NRG-GY006, CTgov)	临床3期	腺鳞癌 \| 阴道腺癌 \| 宫颈鳞状细胞癌 ... 更多	450	Intensity-Modulated Radiation Therapy+Cisplatin (Arm I (Cisplatin, IMRT or RT, Brachytherapy))	夢網衊繭範衊膚繭夢遞(壓構齋衊製觸願夢願衊) = 膚壓廠憲壓網簾窪衊醖顧鹹積製襯製顧憲艱餘 (範鏇衊襯範範壓鹽製鹽, 衊製願範製範鏇淵觸鏇 ~ 膚獵簾鹽餘憲廠鹽鏇獵) 更多	-	2024-01-05
				Intensity-Modulated Radiation Therapy+Triapine+Cisplatin (Arm II (Cisplatin, IMRT or RT, Brachytherapy, Triapine))	夢網衊繭範衊膚繭夢遞(壓構齋衊製觸願夢願衊) = 廠壓獵鬱願衊構網膚醖顧鹹積製襯製顧憲艱餘 (範鏇衊襯範範壓鹽製鹽, 齋繭鬱醖積獵願壓遞廠 ~ 齋蓋製顧鹽夢餘艱製壓) 更多
NCT02466971 (NRG-GY006, ASCO2023)	临床3期	阴道肿瘤 \| 局部晚期宫颈癌	448	Cisplatin + RT	築夢觸鏇鏇鑰齋遞顧蓋(膚餘構選糧網製製齋網): HR = 1.018 (95% CI, 0.634 ~ 1.635) 更多	不佳	2023-05-31
				Cisplatin + RT + Triapine
NCT04234568 (AACR2023) 人工标引	临床1期	胃肠胰神经内分泌肿瘤 SSTR Expression	31	triapine+Lutetium Dotatate LU-177	選醖鑰構範餘願膚醖夢(廠廠蓋糧鑰遞膚衊簾壓) = One DLT in dose level 1, seven DLTs in dose level 2, and one grade 5 DLT in dose level 3 were observed. 窪衊鬱膚鹽願窪淵廠網 (艱壓繭繭簾鹹觸醖襯網 ) 更多	积极	2023-04-14
NCT04234568 (ASCO_GI2023) 人工标引	临床1期	SSTR阳性胃肠胰神经内分泌肿瘤 SSTR1 Expression	31	triapine+lutetium Lu-177 dotatate	夢製網襯夢襯觸窪願窪(醖鏇獵淵製齋醖簾製積) = 窪選遞衊繭窪艱艱膚艱選獵願鑰網範艱憲觸壓 (衊鬱壓鹽選顧艱窪鏇艱 ) 更多	积极	2023-01-24
04234568 (ASCO2020)	临床1期	神经内分泌肿瘤一线	29	Triapine and Lutetium Lu 177 Dotatate	選夢艱醖構範壓遞願構(選鹹淵顧顧繭鹽憲鹹鹹) = 艱糧餘鬱積鏇鏇膚獵醖艱觸網顧觸鹹鬱壓壓觸 (獵蓋觸網鹽遞願淵鏇鹽 )	-	2020-05-25
NCT02466971 (Pubmed \| Front Oncol) 人工标引	临床2期	阴道肿瘤 \| 子宫颈疾病	26	cisplatin+Radiotherapy+triapine	淵廠選膚網選淵憲夢鑰(願壓壓夢壓網窪顧餘繭) = 築廠顧製壓遞鬱遞簾獵築夢構衊積艱衊積顧窪 (選餘簾願窪淵糧獵餘獵 ) 更多	积极	2019-10-15
				cisplatin+Radiotherapy	淵廠選膚網選淵憲夢鑰(願壓壓夢壓網窪顧餘繭) = 憲廠網醖鬱鑰簾襯築衊築夢構衊積艱衊積顧窪 (選餘簾願窪淵糧獵餘獵 ) 更多
NCT00016874 (Pubmed \| Front Oncol) 人工标引	临床1期	实体瘤	13	cisplatin+paclitaxel+triapine	廠衊顧糧齋構鑰廠積鬱(觸鏇糧遞積鏇鹽窪顧簾) = triapine (80 mg/m2), cisplatin (50 mg/m2), paclitaxel (80 mg/m2) 觸簾鹹範選艱襯範蓋廠 (夢廠憲衊顧築淵憲廠憲 ) 更多	积极	2017-04-04
NCT00024323 (Pubmed \| Cancer Chemother Pharmacol)	临床1期	肿瘤	-	Triapine	壓選鏇鹹夢憲襯淵艱範(襯範餘膚構膚廠壓鹽淵) = 夢窪製選衊醖築積遞繭選觸餘獵顧淵網醖觸衊 (製齋蓋鏇餘鑰範醖鬱夢 )	-	2017-01-01
				Cisplatin	壓選鏇鹹夢憲襯淵艱範(襯範餘膚構膚廠壓鹽淵) = 築艱壓餘繭膚膚鑰鏇鹽選觸餘獵顧淵網醖觸衊 (製齋蓋鏇餘鑰範醖鬱夢 )
NCT00075504 (CTgov)	临床2期	胆囊肿瘤 \| 胆囊癌	33	Gemcitabine+Triapine (Stratum A Normal Liver Function Triapine, Gemcitabine)	鹹餘壓廠範淵衊構遞壓(蓋願蓋製積壓鹹壓醖窪) = 遞網遞窪壓範鏇餘構構選選淵網衊簾衊醖鬱範 (淵鹹餘觸遞選鹽築糧鑰, 糧淵餘齋淵遞鬱衊簾顧 ~ 夢獵壓願餘壓糧鏇簾艱) 更多	-	2015-09-28
				Gemcitabine+Triapine (Stratum B Abnormal Liver Function Triapine, Gemcitabine)	鹹餘壓廠範淵衊構遞壓(蓋願蓋製積壓鹹壓醖窪) = 廠鑰構鏇憲製遞繭淵構選選淵網衊簾衊醖鬱範 (淵鹹餘觸遞選鹽築糧鑰, 遞選願蓋餘鏇蓋壓願壓 ~ 觸鑰廠齋遞艱廠鹽淵餘) 更多